top of page
Dr. Knowlittle
This one comes out of the past, but it is about a fear as old as time . . . or at least as old as Merck, namely that testing in animals...
0 comments
Data with destiny
Imagine you have discovered a hit compound to treat drug addiction. Before you drop $1 billion on its development, wouldn’t you want to...
0 comments
Thymus up: the hidden powers of HCAC7
Some autoimmune diseases, like lupus, affect multiple tissues, but some, like inflammatory bowel disease, affect only specific types. A...
0 comments
New rules!
The pharmaceutical industry has long stayed humble with their rules for successful drug development: "We’re not bigger than the game!"...
0 comments
Purposeful repurposing
Drug repurposing is seen to be a major growth area in the drug development field because it trades the unsolved problem of attrition for...
0 comments
Could GeneCentrix's Historeceptomics Profiler have saved millions for Roche and PTC Therapeutics
Roche and PTC’s Spinal Muscular Atrophy clinical drug trials were waylaid by an unexpected tissue specific effect. After the trial had...
0 comments
Finally getting a handle on rare variations
Rare variations in genomic data have long been the bugaboo of computational biologists, those soldiers at the forefront of personalized...
0 comments
Blog: Blog
bottom of page